AR019226A1 - Uso de texafirinas en enfermedad mediada por macrofagos - Google Patents

Uso de texafirinas en enfermedad mediada por macrofagos

Info

Publication number
AR019226A1
AR019226A1 ARP990103250A ARP990103250A AR019226A1 AR 019226 A1 AR019226 A1 AR 019226A1 AR P990103250 A ARP990103250 A AR P990103250A AR P990103250 A ARP990103250 A AR P990103250A AR 019226 A1 AR019226 A1 AR 019226A1
Authority
AR
Argentina
Prior art keywords
texafirines
macrophagos
medium disease
texaphyrins
macrophages
Prior art date
Application number
ARP990103250A
Other languages
English (en)
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of AR019226A1 publication Critical patent/AR019226A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Usos de una texafirina en la preparacion de una composicion farmacéutica para usar en imágenes y/o tratamientos de enfermedades mediadas por macrofagosal hacer sensible los efectos de un agente coterapéutico. Se proveen texafirinas para mejorar la citotoxicidad de agentes terapéuticos en enfermedadesmediadas por macrofagos puesto que se ha demostrado que las texafirinas se acumulan en macrofagos.
ARP990103250A 1998-07-06 1999-07-05 Uso de texafirinas en enfermedad mediada por macrofagos AR019226A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11050998A 1998-07-06 1998-07-06

Publications (1)

Publication Number Publication Date
AR019226A1 true AR019226A1 (es) 2001-12-26

Family

ID=22333401

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103250A AR019226A1 (es) 1998-07-06 1999-07-05 Uso de texafirinas en enfermedad mediada por macrofagos

Country Status (8)

Country Link
EP (1) EP1094840A1 (es)
JP (1) JP2002519390A (es)
KR (1) KR20010079498A (es)
AR (1) AR019226A1 (es)
AU (1) AU4860899A (es)
CA (1) CA2336134A1 (es)
NO (1) NO20010044L (es)
WO (1) WO2000001414A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6163988A (en) * 1995-05-17 2000-12-26 Rockland, Inc. Assembly connectable to an operating arm of a machine for performing work functions
RU2106146C1 (ru) 1995-07-17 1998-03-10 Институт элементоорганических соединений РАН Средство для подавления опухолевого роста
WO2001032210A2 (en) 1999-10-29 2001-05-10 Pharmacyclics, Inc. Compositions for treating atheroma and neoplastic tissue
US7579338B2 (en) 1999-10-29 2009-08-25 Pharmacyclics, Inc. Methods and compositions for treating atheroma, tumors and other neoplastic tissues
JP2003012547A (ja) * 2001-06-27 2003-01-15 Meiji Seika Kaisha Ltd インスリン依存性糖尿病の診断剤および治療剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5419760A (en) * 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6008211A (en) * 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
US5913884A (en) * 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy

Also Published As

Publication number Publication date
NO20010044D0 (no) 2001-01-04
EP1094840A1 (en) 2001-05-02
JP2002519390A (ja) 2002-07-02
AU4860899A (en) 2000-01-24
CA2336134A1 (en) 2000-01-13
NO20010044L (no) 2001-03-01
KR20010079498A (ko) 2001-08-22
WO2000001414A1 (en) 2000-01-13

Similar Documents

Publication Publication Date Title
CL2004000931A1 (es) Pelicula consumible adaptada para adherirse y disolverse en la cavidad bucal que comprende un almidon modificado y un agente farmaceuticamente activo.
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
ES2081110T3 (es) Composicion cosmetica o farmaceutica, particularmente dermatologica, destinada a favorecer la pigmentacion de la piel o de los cabellos, que contiene un extracto de cyperus y su procedimiento de fabricacion.
ATE232396T1 (de) Oxydiertes thymosin beta 4
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
BR0010531A (pt) Composições e usos de et743 para tratamento de câncer
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
ES2158597T3 (es) Compuestos bioaromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
AR019226A1 (es) Uso de texafirinas en enfermedad mediada por macrofagos
ES2136954T3 (es) Utilizacion de al menos un agua termal de vichy como antagonista de sustancia p.
PT1124566E (pt) Laxativo osmotico nao fermentado para o tratamentoe a prevencao dos cancros colorectais
ES2159697T3 (es) Utilizacion de un antagonista de cgrp para tratar los liquenes y los pruritos y composicion obtenida.
PT900563E (pt) Producao de formulacoes farmaceuticas para o tratamento de edema e doencas venosas
AR015956A1 (es) Composiciones de citoquinas oromucosales y usos de las mismas
SE0001916D0 (sv) Novel formulation
MX9805065A (es) Nuevos derivados bi-aromaticos del dibenzofurano y su utilizacion en medicina humana o veterinaria asi como en cosmetica.
PA8496801A1 (es) Complejo farmaceutico
ATE258801T1 (de) Matrixprotein zusammensetzungen um apoptose zu induzieren
ES2090671T3 (es) Composiciones para la pigmentacion de la piel o de los cabellos que contienen un extracto de marrubium vulgare.
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
BR9908358A (pt) Preparação para tratamento da disfunção erétil
IT7824118A0 (it) Derivati di glicosidi benzopiraniche, loro procedimento di ottenimento e loro utilizzazione nella terapeutica umana.